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Background: Infection by any one of 15 high risk human papillomavirus (hrHPV) types causes most invasive cervical
cancers. Their oncogenic genome is encapsidated by L1 (major) and L2 (minor) coat proteins. Current HPV prophylactic
vaccines are composed of L1 virus-like particles (VLP) that elicit type restricted immunity. An N-terminal region of L2
protein identified by neutralizing monoclonal antibodies comprises a protective epitope conserved among HPV types,
but it is weakly immunogenic compared to L1 VLP. The major antigenic capsid protein of adenovirus type 5 (Ad5) is
hexon which contains 9 hypervariable regions (HVRs) that form the immunodominant neutralizing epitopes. Insertion
of weakly antigenic foreign B cell epitopes into these HVRs has shown promise in eliciting robust neutralizing antibody
responses. Thus here we sought to generate a broadly protective prophylactic HPV vaccine candidate by inserting a
conserved protective L2 epitope into the Ad5 hexon protein for VLP-like display.
Methods: Four recombinant adenoviruses were generated without significant compromise of viral replication by
introduction of HPV16 amino acids L2 12–41 into Ad5 hexon, either by insertion into, or substitution of, either hexon
HVR1 or HVR5.
Results: Vaccination of mice three times with each of these L2-recombinant adenoviruses induced similarly robust
adenovirus-specific serum antibody but weak titers against L2. These L2-specific responses were enhanced by
vaccination in the presence of alum and monophoryl lipid A adjuvant. Sera obtained after the third immunization
exhibited low neutralizing antibody titers against HPV16 and HPV73. L2-recombinant adenovirus vaccination without
adjuvant provided partial protection of mice against HPV16 challenge to either the vagina or skin. In contrast,
vaccination with each L2-recombinant adenovirus formulated in adjuvant provided robust protection against vaginal
challenge with HPV16, but not against HPV56.
Conclusion: We conclude that introduction of HPV16 L2 12–41 epitope into Ad5 hexon HVR1 or HVR5 is a feasible
method of generating a protective HPV vaccine, but further optimization is required to strengthen the L2-specific
response and broaden protection to the more diverse hrHPV.* Correspondence: oaibeanu@aol.com
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Cervical cancer has an annual global incidence of ap-
proximately 500,000 cases, with about 250,000 disease
related deaths. Most (>85 %) of these deaths occur in
developing countries, notably in sub-Saharan Africa,
southeast Asia, and South America, which currently
harbor the heaviest disease burden [1]. It has been estab-
lished that cervical cancer is mostly a sexually trans-
mitted disease that results from persistent infection with
'high-risk' oncogenic human papillomaviruses (HPV),
with such HPV DNA being present in >95 % of cervical
cancers diagnosed [2]. The most prevalent oncogenic
HPV types are 16 and 18 causing approximately 50 %
and 20 % of cervical cancer cases respectively. A dozen
other HPV types, notably HPV31, 33, 45, 52, 56, and 58
are also oncogenic, together accounting for about 30 %
of cases, with each type responsible for a small fraction
of cervical cancer [3]. An ideal HPV vaccine therefore
would protect against all high risk HPV types [4].
Most HPV infections are asymptomatic or regress in
immune-competent individuals, but it is the small
fraction of persistent cases that can progress to cancer.
Human papillomaviruses are non-enveloped, small DNA
viruses with a genome that is approximately 8 kilobases
and encodes eight genes; six early genes (E1, E2, E4, E5,
E6, E7) and two late genes (L1, and L2) [5]. HPV infects
basal cells in the epithelium following genital abrasions
sustained during sexual activity with infected individuals.
The early viral proteins affect the host cell cycle in favor
of viral replication whereas the late proteins (L1 and L2)
assemble into a capsid structure around the histone-
bound viral genome to form new viral particles [6, 7].
Infectious viral particles are released during the natural
process of shedding of the terminally differentiated epi-
thelial cells, likely aided by E4’s capacity to disrupt kera-
tin filaments [8]. HPV infection is highly prevalent
among sexually active adults globally, and HPV-related
diseases are expected to continue as a major global
healthcare problem in developing countries due to lim-
ited implementation of accepted preventive measures.
The commercially available HPV vaccines are Gardasil
(Merck and Company, NJ, USA), and Cervarix
(GlaxoSmithKline, UK). Both vaccines are polyvalent,
and contain viral-like particles (VLPs) assembled from the
L1 major capsid protein of HPV 16 and 18 types. Gardasil
also contains HPV 6 and 11 VLPs, and a new version,
Gardasil 9, which also contains HPV31, 33, 45, 52, 58 L1
VLP was recently licensed [9]. While Gardasil 9 targets
these dominant α7 and α9 species, it does not target all
high risk HPV types, including HPV56 and HPV73 which
are α6 and α11 species respectively. These vaccines do not
contain live viral material, but induce both a potent neu-
tralizing antibody response and durable protection against
the targeted genotypes [10–13]. The immunodominantneutralizing epitopes in the hypervariable loops of the L1
protein are not cross-reactive among HPV types [14, 15].
Therefore, there is limited or ineffective protection against
other oncogenic HPV types and highly multivalent formu-
lations are required for broad coverage [11]. Other limita-
tions of the current L1 based vaccines are cost, need for
vaccine cold-chain, continued need for cervical screening,
and the need for more than one injection to complete the
vaccine course. Even in the United States, vaccination
coverage remains low in adolescent females [16]. In many
developing countries, national HPV vaccination programs
do not even exist. There is a need for an alternative
prophylactic HPV vaccine to expand access globally that is
inexpensive, stable at tropical temperatures, broadly cross-
protective against high risk HPV, and preferably adminis-
tered as single dose for compliance [9].
The L2 protein is an immunogen whose N terminal
region is highly conserved among HPV types and can
elicit protective immunity in animal papillomavirus mo-
dels [17]. L2 is required for infection, and its cleavage at
residue 11 of HPV16 L2 by furin is an essential step
[18]. Furthermore, a putative transmembrane domain
between residues 45–67 of L2 is also critical, possibly to
facilitate crossing the limiting membrane during infec-
tion [19]. Several groups have identified conserved pro-
tective epitopes between these regions, such as residues
17–36 [20] and 28–42 [21, 22] of HPV16 L2 [23], that
can potentially serve as a single broadly protective im-
munogen. However, despite the use of strong adjuvants,
these peptide epitopes are weakly immunogenic com-
pared to L1 VLP [22].
A promising strategy to enhance the immune response
to these L2-based protective peptides is their substitu-
tion for, or insertion into the immunodominant neutral-
izing epitope of a heterologous virus [24]. With the
availability of detailed structural data for adenoviruses
[25, 26], several investigators have used various ade-
novirus types as platforms for capsid display of foreign
antigens to induce protective immunity against a host of
human pathogens [27–29]. Such strategy exploits several
potentially advantageous characteristics of human ade-
noviruses. Human adenoviruses typically cause non-fatal
respiratory and gastrointestinal infections. Orally admin-
istered single dose vaccines containing lyophilized fully
replication competent adenovirus 4 and 7 have been in
use for decades, and have proven to be highly effective
and safe [30, 31]. The hexon protein of adenovirus is
exposed at the viral surface and contains nine hyper-
variable regions (HVRs). The HVRs display adenoviral
epitopes that are responsible for serotype-specific antige-
nicity, and their specific amino acid sequences can be
freely modified [32]. The work that is presented in this
paper is based on the hypothesis that it is feasible to
generate protective neutralizing antibodies against a
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16 L2 antigenic peptide sequence displayed in HVRs of
the human Ad5 hexon capsid protein.
Results
Generation of recombinant adenoviruses displaying L2
Immunization of rabbits with a synthetic HPV16 L2 17–36
peptide coupled to KLH carrier or HPV16 L2 1–88 poly-
peptide in Freund’s adjuvant was previously shown to
induce a moderate titer antibody response capable of
neutralizing diverse HPV types [20, 23, 33]. To explore the
potential of capsid display of L2 to trigger a robust cross-
neutralizing antibody response without the use of adjuvant,
we generated four recombinant adenoviruses. The HPV16
L2 12–41 region was selected for display since this spans
the furin-cleavage site through to the edge of a putative
transmembrane domain, and encompasses the RG-1 and
other cross-protective epitopes at 17–36 [20] and 28–42
[21, 22]. The optimal approach to display the L2 epitope in
the HVRs of hexon is unclear with respect to both viral
propagation and immunogenicity. Therefore the L2 epi-
tope was either inserted into the middle of an HVR, or
used to replace the HVR sequence (Table 1). Likewise,
adenovirus contains multiple HVR, and it is not known
which is appropriate for display of L2. Since HVR1 and
HVR5 have previously been used to display heterologous
epitopes of 24 and 66 amino acids (reviewed in [34]), the
L2 epitope was inserted or substituted into both (Table 1)
by recombination. The presence of the desired HPV
antigen in the hexon HVRs of plaque-purified recombinant
adenoviruses was confirmed by Western blot using a
monoclonal antibody (RG-1) against HPV16 L2 17–36
(prepared by Harlan Laboratories). Western blots revealed
an RG1-reactive band of approximately 120 KDa in all four
recombinant adenoviruses, consistent with the expected
size of adenovirus hexon protein containing the L2 insert,
whereas none reacted with negative control monoclonal
antibody 2A10. Reaction with antibody to adenovirusTable 1 Summary of production of L2-recombinant Ad5 virions.
Shown are the designation of each L2-recombinant adenovirus,
the nature of the L2 insert, the site of hexon into which it was
inserted, the mode of insertion and the pfu of virus obtained
upon a standard preparation
Construct Insert (a.a.) Hexon site (a.a.) Mode Particles/ml
5 ins HPV16 271–272 HVR5 Insertion 2.2 × 1012
L2 12–41
5 sub HPV16 271–281 HVR5 Substitution 2.37 × 1012
L2 12–41
1 sub HPV16 138–167 HVR1 Substitution 1.80 × 1012
L2 12–41
1 ins HPV16 128–129 HVR1 Insertion 1.76 × 1012
L2 12–41capsid proteins by Western blot revealed a normal comple-
ment of adenovirus virion components. All four L2 recom-
binant adenoviruses replicated efficiently in 293 cells, as
can be seen from the high titers observed for the standard
virion preparations (Table 1).
Immunogenicity of L2-recombinant adenovirus
Groups of 5 Balb/c mice were immunized three times at
3 week intervals either with recombinant adenoviruses
displaying the L2 epitope or a recombinant that displays
an irrelevant epitope. ELISA to detect antibodies against
wild type Ad5 particles and HPV L2 were performed on
the serum collected at 3 week intervals (Fig. 1a). Every
mouse in each group produced antibodies against the
adenovirus vector. In general, individual mice responded
to the first immunization with anti-adenovirus titers of
approximately 103, with increases after each subsequent
immunization to maximum titers >104 after the third
dose. The use of an adjuvant (alum and monopho-
sphoryl lipid A) did boost the anti-adenovirus antibody
titers. Overall, there was no clear difference in the in-
duction of adenovirus particle-specific antibodies by the
four L2 recombinant adenoviruses, suggesting that nei-
ther insertion into, nor substitution of HVR1 or HVR5
with the L2 peptide disrupts the capsid structure or anti-
genicity substantially.
Antibody titers to L2 were lower than to adenovirus,
but increased after each boost (Fig. 1b). Furthermore,
antibody responses to HPV L2 were noticeably increased
with the use of adjuvant. There was no significant dif-
ference in the induction of L2-specific antibody by the
four recombinant adenoviruses (Fig. 1b). Since Gardasil
is made up of L1 viral like particles, the mice immunized
with Gardasil produced no antibodies to HPV L2 or
adenovirus, similar to the PBS negative control mice
(not shown).
Immunization with L2-recombinant adenoviruses induces
antibodies that neutralize HPV
Sera collected 3 weeks after the third recombinant adeno-
virus immunization were titrated against HPV16 pseudo-
virions in an in vitro neutralization assay (Fig. 2a, b). All
mice in the control (Gardasil) group produced high titer
neutralizing antibodies. In the negative control (PBS and
HA recombinant) groups none of the mice produced neu-
tralizing antibodies, as expected. There was little evidence
of HPV16 neutralizing antibody, as measured using the
standard pseudovirion-based assay, in the sera of mice
vaccinated with the L2 recombinant adenoviruses three
times in the absence of adjuvant, despite reactivity in L2
ELISA. In the mice that received adjuvant each of the four
recombinant adenoviruses induced low HPV16 neutra-
lizing antibody titers (Fig. 2b). Similar results were ob-
tained for cross-neutralization of HPV73 (Fig. 2c), a high
Fig. 1 Adenovirus and L2-specific serum antibody response after vaccination of mice with L2-recombinant adenoviruses either with or without
adjuvant. Legend: Balb/c mice (5/group) were vaccinated s.c. three times at 3 week intervals with 1010 L2 or HA-recombinant adenovirus particles
either with 50 μg aluminum hydroxide gel and 5 μg monophosphoryl lipid A (shaded boxes) or without adjuvant (clear boxes) in a total volume
of 150 μL/dose, or controls Gardasil (0.1x human dose) or buffer. Serum was collected 3 weeks after each immunization (i.e. bleed numbers b1,
b2 or b3) and two-fold dilutions tested by ELISA. ELISA titers against adenovirus (a) or L2 (b) are shown as mean + SEM. HA: mice immunized with
the HA recombinant control virus
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Gardasil 9 vaccine [9]. This likely reflects the near perfect
conservation of the 17–36 epitope recognized by the
cross-neutralizing monoclonal antibody RG1 [20], as
shown in Fig. 2d.
Immunization with L2-recombinant adenovirus protects
mice against homologous but not heterologous HPV type
challenge
The standard HPV in vitro neutralization assay protocol is
poorly sensitive for L2-specific antibodies, whereas chal-
lenge models are both more biologically relevant and sen-
sitive, i.e. L2-specific antibodies have a more potent effect
in vivo. Therefore, vaccine efficacy was evaluated by
challenging immunized mice with HPV pseudovirus (PsV)
encapsidating a luciferase reporter. Immunized mice were
first challenged intra-vaginally with HPV16 pseudovirus
(Fig. 3a and b). The mice vaccinated with Gardasil 4,
which contains HPV16 L1 VLP, were completely pro-
tected from experimental challenge (p < 0.01). The mice
vaccinated in the absence of adjuvant with each L2-
recombinant adenovirus were only partially protected
from HPV16 challenge, but each was significant com-
pared to mice immunized with PBS or the HA recom-
binant (p < 0.01 for 5Sub, 1Sub and 1Ins, p < 0.05 for 5Ins
versus PBS). Cutaneous challenge was then conductedwith HPV16 in a separate study of mice immunized using
either HPV16 L2 17–36 synthetic peptide or the recom-
binant adenoviruses 5Sub, 5Ins or 1Sub without adjuvant.
Partial protection was observed in those vaccinated with
L2-recombinant adenovirus 5Sub and 5Ins, but not 1Sub
or the HA recombinant (Fig. 4). Gardasil 4 was completely
protective against HPV16 cutaneous challenge, whereas
vaccination with HPV16 L2 17–36 synthetic peptide was
not. The failure of the peptide alone to protect reflected
its previously described lack of immunogenicity without
T-cell help.
Vaccination with each L2 recombinant in the presence
of adjuvant induced dramatically better protection in the
vaginal challenge model. In a majority of recombinant-
vaccinated mice, luminescence was reduced to a level
indistinguishable from that of Gardasil 4-vaccinated ani-
mals, and every mouse immunized with recombinant ad-
enoviruses 5Ins and 1Ins was fully protected (p < 0.05
for all four L2 recombinant adenoviruses). The HA re-
combinant control had no significant impact on HPV16
infection.
HPV16 and HPV56 are high risk viruses of the α9 and
α6 species respectively, and the latter is not targeted by
Gardasil 9. Since L2-specific antibodies are typically cross-
protective, and we observed cross-species neutralization
of HPV73 (α11 species), we examined protection against a
Fig. 2 HPV16 and HPV73 neutralizing antibody elicited by vaccination of mice with L2-recombinant adenoviruses either with or without adjuvant.
Legend: Balb/c mice (5/group) were vaccinated s.c. three times at 3 week intervals with 1010 L2 or HA-recombinant adenovirus particles either in
the absence (a) or presence (b) of adjuvant (50 μg aluminum hydroxide gel and 5 μg monophosphoryl lipid A), or controls Gardasil (0.1x human
dose) or phosphate-buffered saline (PBS). Serum was collected 3 weeks after the final immunization and two-fold dilutions tested by for in vitro
neutralization of HPV16 (A, B) or HPV73 (c) pseudovirions. Purified RG-1 monoclonal antibody was included as a positive control for L2-specific
neutralization and diluted from 1 μg/μL. A neutralization titer of <1:50 is considered Not Detectable (ND) and mean titer is shown. (d) A web-based
T-coffee tool was used for the CLUSTAL W (1.83) multiple sequence alignment (http://www.ebi.ac.uk/Tools/msa/tcoffee/) comparison of the amino acid
sequences of HPV16 L2 12–41 and the comparable regions of HPV56 and HPV73 color coded by amino acid side chain. The alignment is shown and
identity is marked below with an asterisk and a conservative change with a colon
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ogous intravaginal challenge with HPV56 pseudovirus
(Fig. 3c and d), that diverges from the 30 amino acid
HPV16 L2 epitope sequence at 9 positions (Fig. 2d). The
PBS injected mice showed high luciferase activity, indicat-
ing they were infected. The Gardasil vaccinated group was
not significantly protected against HPV56, consistent with
the type-restricted response to L1 VLP and the absence of
this type from the vaccine. Similarly, mice immunized
with the L2-recombinant adenoviruses either with or
without adjuvant also showed no significant protection
against HPV56 irrespective of the recombinant virus con-
struct used (Fig. 3).
Discussion
Prior animal experiments by other investigators have
demonstrated the ability to induce cross-protective
antibodies against bovine and rabbit papillomaviruses by
immunization with polypeptides derived from the N-
terminus of L2 [35, 36]. L1 constitutes the bulk of the
capsid structure and is immunologically dominant [37],
and a minimal or undetectable L2-specific antibodyresponse is observed in the setting of combined experi-
mental L1 and L2 VLP vaccination or natural infection.
Presumably the papillomaviruses have evolved to render
these broadly cross-type protective L2 epitopes very
poorly immunogenic to permit infection of a single host
with multiple types. This might be achieved by holding L2
cross-type protective epitopes (whose sequences are con-
served because of critical function during the infectious
process) below the capsid surface until initiation of infec-
tion or simply by virtue of distant spacing of L2 epitopes
on the capsid surface to prevent a typical L1 VLP-like re-
sponse. High density virus-like display of conserved but
sub-dominant protective L2 epitopes represents a pro-
mising strategy to induce potent and durable L2-specific
antibody responses [24, 38]. Animal studies have demon-
strated the feasibility of protective L2 epitope display in
the Tobacco Mosaic Virus (TMV) with successful produc-
tion of low titers (50–500) of protective antibodies when
using RIBI adjuvant. When vaccinating with TMV display-
ing a conserved CRPV L2 epitope, robust protection was
observed against CRPV but not ROPV, suggesting that
cross-protection was much weaker than efficacy against
Fig. 3 Protection of against vaginal challenge with HPV after vaccination with L2-recombinant adenoviruses either with or without adjuvant.
Legend: Balb/c mice (5/group) were vaccinated s.c. three times at 3 week intervals with 1010 L2- or HA-recombinant adenovirus particles either in
the absence (a,c) or presence (b,d) of adjuvant (50 μg aluminum hydroxide gel and 5 μg monophosphoryl lipid A), or controls Gardasil (0.1x human
dose) or phosphate-buffered saline (PBS). Mice were challenged intravaginally with either HPV16 (a,b) or HPV56 (c,d) pseudovirions at 4 weeks after
the final immunization. Three days later the infection was assessed by imaging of bioluminescence (RLU). The background bioluminescence of
unchallenged mice (BK) is shown. **p < 0.01, *p < 0.05
Fig. 4 Partial protection against cutaneous challenge with HPV16 after
vaccination with L2-recombinant adenoviruses without adjuvant.
Legend: Balb/c mice (5/group) were vaccinated three times s.c. at
3 week intervals with either wild type or L2-recombinant Ad5 particles
in the absence of adjuvant, or controls Gardasil (0.1x human dose) or
synthetic HPV16 L2 17–36 peptide (20 nmol QLYKTCKQAGTCPPDIIPKV).
Mice were shaved and then challenged on their belly with HPV16
pseudovirions after the final immunization and three days later the
infection was assessed by imaging of bioluminescence (RLU). The data
are presented as mean + SEM after subtraction of the mean background
bioluminescence of unchallenged mice
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consistent with the observations herein, including the
moderate L2-specific antibody response and the type-
restricted protection despite use of a relatively conserved
protective epitope.
Adenoviruses are large non-enveloped DNA viruses
which cause mostly short, transient upper respiratory
and gastrointestinal infections in humans. In contrast to
TMV, however, adenovirus can replicate in humans, and
adenoviruses typically induce robust host immune re-
sponses. For decades now, the US military has been
using live, orally administered single dose vaccines to
immunize recruits against adenoviruses 4 and 7, with no
reported significant adverse events [30, 31]. The major
adenovirus capsid protein, hexon, is a 960 amino acid
polypeptide present in 720 copies per viral particle.
Hexon is capable of inducing a strong host antigenic re-
sponse. Hexon contains 9 HVRs that possess epitopes
which are responsible for antigenic diversity among
adenovirus serotypes [25]. The amino acid sequences of
HVRs can be modified with little effect on viability, and
several investigators have used adenoviruses as viral
vectors for capsid display of antigens to induce pro-
tective immunity against a host of human pathogens in-
cluding pseudomonas, trypanosoma, plasmodium, and
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this study demonstrate the feasibility of the capsid dis-
play of an L2 epitope by insertion into HVR1 and 5 of
the adenovirus 5 hexon.
Experiments using influenza epitopes [43] have shown
that HVR length can affect the immune response probably
due to the position and conformation of the HVRs within
the hexon sequence. Specifically, HVR5 was shown to be
more permissive for larger sequence insertions compared
to HVR2, and this correlated with higher titer immune re-
sponses. Due to the limited capacity of the adenovirus
HVRs, it was not clear whether insertion or substitution
of the HVR with the first ~100 residues of L2 would be
feasible without compromising replication competence.
However, both our fairly short HPV L2 substitutions and
insertions were successfully incorporated in the hexon
structure without compromising virion replication. Fur-
ther, both insertion and substitution recombinant adeno-
viruses elicited similar L2 antibody responses.
We have also demonstrated that the recombinant vac-
cine constructs were capable of inducing neutralizing
antibodies in sufficient titers to confer protection against
HPV16, as evidenced by the challenge experiments. Use
of an adjuvant (alum +monophosphoryl lipid A (MPL),
similar to that incorporated in the licensed HPV vaccine
Cervarix) enhanced immunogenicity. Given that the re-
combinant adenoviruses are non-replicating in mice, we
postulate that the adjuvant was therefore relevant to
boost antibody response. It is reasonable to expect that
in a human, our viable recombinant viruses might be
independent of co-administered adjuvant given the like-
lihood that viral lysis of infected cells will trigger local
inflammation [44], and that the infection is likely to per-
sist for days to a few weeks, as do infections with the
military vaccine strains [45].
The L2-recombinant adenoviruses failed to induce
cross-protective immunity against HPV56. This is sur-
prising in light of the promising results obtained when
vaccinating with KLH-coupled HPV16 L2 17–36 peptide
in Freund’s adjuvant [20, 46] or when this epitope is
inserted into the DE loop of the HPV16 L1 VLP capsid
[47, 48]. Several explanations are proffered. First, the L2
epitopes of HPV16 and HPV56 may not be sufficiently
similar to provide cross-protection given the weak
HPV16 L2-specific response measured by ELISA and
neutralization assays. This is the most likely reason as
there is considerable difference, 9 of 30 residues, be-
tween these types in the L2 28–41 neutralizing epitope
region [21, 22], as can be seen in Fig. 2d, and the ability
to cross-neutralize HPV73 which is more similar in this
region (only 2 changes in 30 residues, one of which is
conservative). Second, the HPV L2 epitope as displayed
in our recombinant adenoviruses, may suffer from non-
native spatial conformation that could affect the breadthof the immune response or promote the production of
non-neutralizing antibodies. Recent work has shown
that cross-protection against the HPV L2 epitope is in-
deed affected by the flexibility of the epitope during
capsid display [49], i.e. greater cross-protection was ob-
served when one end of the L2 epitope was free. Third,
in natural infections, cleavage of furin near the N
terminus of L2 causes one end of the epitope used here
to be free, presumably affecting conformation of the L2
epitope. The capsid display recombinant adenoviruses
lacked furin cleavage sites, and were inserted or
substituted into the hexon with both ends attached. It
is reasonable to try to increase flexibility in the L2
display by using glycine-serine-glycine (GSG) flankers
for example, or by inserting furin cleavage sites to help
mimic native configuration of L2 in a replication-
capable setting. Insertion/substitution of L2 into the
other 7 HVRs might increase efficacy, and it may be ad-
vantageous to insert L2 into multiple HVR in a single
construct to increase epitope density, which is associ-
ated with higher immunogenicity [38]. An alternative
approach to enhance the breadth of protection is to in-
sert L2 epitopes from different HPV types into different
HVR, as described by Nieto et al. for AAV [50], or to
insert a concatemer of L2 epitopes of different HPV
types into a single HVR [51]. Alternatively, the use of a
consensus sequence might be considered but this could
reduce responses to key types such as HPV16.
Prior adenovirus exposures are not uncommon in
human adults and there is a general concern about the
potential impact of pre-existing immunity against a re-
combinant adenovirus based vaccine in (future) clinical
application. A study using an Ad5 based tuberculosis
vaccine did not confirm a postulated deleterious effect
of pre-existing antibodies on the antigenicity of the
vaccine constructs that were tested [52]. However, this
vaccine is replication deficient and pre-existing anti-
bodies may be even more problematic for live vaccines.
Strategies to bypass this potential problem include the
use of less-commonly occurring human adenovirus
types.Conclusions
Our studies demonstrate the antigenicity of capsid dis-
play of the HPV L2 epitope using an adenovirus vector.
This represents an initial step in the search for an alter-
native to the L1 VLP based prophylactic vaccines in use
today. Continued optimization of the display of L2 by
hexon clearly will be required. If successful and safe, L2-
recombinant adenovirus vaccines could potentially be
produced inexpensively, and simply administered in a
heat-stable single oral dose for improved patient access
and compliance.
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Insertion of L2 epitope into HVRs
Constructs containing the L2 sequence either as a sub-
stitution or insertion into adenovirus 5 hexon protein
hypervariable (HVR) regions 5 or as a substitution into
HVR1 were generated by overlapping PCR (Table 1)










and Primer 2 gcaggccggcacctgcccacccgatatcatccccaaggt
ggagggcaagaccatcGCGACCGCAGGCAATGGT
For construct 5Sub, Primer 1
5' cgggtgggcaggtgccggcctgcttgcaggtcttgtacagctgggtggcg
ctggctctCTCAGTAGTTGAGAAA AATTGC
and Primer 2 gcaggccggcacctgcccacccgatatcatccccaagg
tggagggcaagaccatcACTCCTAAAGTGGTATTGTAC
For all three reactions, CGGCGTGCTGGACAGG
GGCCC and GCTGGCTCCGTCAACCC were used as
outside primers. The PCR products were cloned into
plasmid pCR2.1 using the TopoTA system (Invitrogen)
and were subcloned into shuttle plasmid pJMG (Ad5
nucleotides 13255 – 21562, including all of the hexon
gene).
For construct 1Ins, a DNA sequence was directly



















GGTATTGTACA). This includes an EcoRV site to facilitate
screening of recombinant adenoviruses, and encodes Ad5
hexon (19160–19703) with an insertion of HPV16 L2 12 to
41 (RASATQLYKTCKQAG TCPPDIIPKVEGKTI) intoHVR1. This entire sequence was directionally inserted into
pJMG using the flanking ApaI and BsrGI sites.
Generation, isolation and purification of recombinant
adenovirus
For 1Sub, 5Sub and 5Ins recombinant adenoviruses,
engineered hexon DNA fragments were introduced into
the full-length Ad5 genomic plasmid CP08 by phage
lambda red-mediated recombination in E. coli between
CP08 and the shuttle plasmids described above [53],
CP08 carries a full-length Ad5 genome with an insertion
of lacZ in the hexon gene [29]. Following recombination,
E. coli strains that contained the desired recombinants
were identified by restriction enzyme digestion of mini-
prep DNAs with EcoRV. To generate virus from recom-
binant plasmids, linear viral genomic DNA liberated
from the plasmid by digestion with PacI was introduced
into 293 cells by calcium phosphate precipitation [54].
Individual plaques were picked and amplified in 293
cells. Lysates were screened by immunoblotting for re-
activity with the L2 antibody RG-1 to confirm that they
contained the L2 peptide. Recombinant adenovirus 1Ins
was prepared by recombination in transfected 293 cells
between the shuttle plasmid and virion DNA derived
from a viable Ad5 recombinant bearing a Plasmodium
falciparum circumsporozoite epitope (CSP) in hexon
[55]. The recipient DNA was digested with NdeI, which
cleaves the recombinant at a single site in hexon, redu-
cing plaque formation by the parental virus. Plaque puri-
fied recombinant viruses were amplified in 293 cells and
were screened for RG-1 reactivity to detect the L2 epi-
tope and with a CSP-specific monoclonal antibody to
confirm loss of the allelic malaria epitope. All recombin-
ant adenoviruses were plaque-purified and virus particles
were prepared by CsCl density gradient centrifugation
and quantified as described previously [56]. A control re-
combinant that displays an epitope derived from influ-
enza virus A hemagglitinin (HA) was prepared similarly
(C. Deal and G. Ketner, unpublished).
Immunization of mice and HPV challenge
All animal experiments were performed with the prior ap-
proval of the Johns Hopkins University Animal Care and
Use Committee. Female 3–6 week Balb/c mice were ob-
tained from the National Cancer Institute and were immu-
nized by subcutaneous injection with 1 × 1010 recombinant
virus particles suspended in PBS (non-adjuvant group) or
mixed with 50 μg aluminum hydroxide gel and 5 μg
monophosphoryl lipid A in a total volume of 150 μL/dose,
or as a control synthetic HPV16 L2 17–36 peptide
(20 nmol QLYKTCKQAGTCPPDIIPKV). Mice were
boosted with the same recombinant virus dose at 3 weeks
and 6 weeks after initial vaccination. Serum was collected
every 3 weeks. Four weeks after the third immunization,
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Four days after treatment, HPV pseudovirus (PsV) encapsi-
dating a luciferase reporter was used for vaginal challenge,
before and after induction of local epithelial trauma using
an endocervical brush. Each mouse was challenged with
HPV pseudovirions in 20 μL (estimated at 109 particles/
mouse based on L1 content). An equal volume of 3 %
CMC (Carboxymethylcellulose sodium salt, C5013 Sigma,
St Louis MO, USA) in PBS was added to make a total virus
challenge volume of 40 μL per mouse. Mice were anesthe-
tized with isoflurane inhalation to effect prior to adminis-
tration of virus. Half of the challenge dose (20 μL) was
injected into the mouse vaginal vault, followed by insertion
of a cytobrush cell collector that was turned both clockwise
and counter-clockwise 15 times to induce trauma. After re-
moval of the cytobrush, the remaining half of the inoculum
was deposited in the vagina. Three days later, the vaginal
tracts were instilled with luciferin (20 μL at 7 mg/mL) and
the genital area of anaesthetized mice was imaged for
10 min with a Xenogen IVIS200 system [51, 58]. For skin
challenges, a patch on the belly of each anesthetized Balb/c
mouse was closely shaved, first with an electric razor
(Oster Golden 45, blade 40), then repeatedly with a scalpel
blade to remove all traces of hair, and challenged by appli-
cation to the shaved skin of 3 × 109 HPV pseudovirions in
10 μL of 0.6 % CMC. Three days later, the mice were anes-
thetized and injected with luciferin (100 μL at 7 mg/ml),
and their images were acquired for 10 min with a
Xenogen IVIS 200. Equally sized areas encompassing the
site of inoculation were analyzed using Living Image 2.20
software, and plotted after background subtraction. Using
Graphpad software, the results of the challenge were re-
corded [59, 60].
ELISA
For adenovirus, 96 well plates (Immunolon) were coated
overnight at RT with 7.85 × 1011 wild type adenovirus
particles/plate in PBS. For L2, 96 well NUNC Maxisorp
plates were coated and incubated overnight at 4 °C with
a bacterially-expressed L2 antigen comprising residues
11–88 of HPV16 and seven other alpha HPVs in tandem
(100 ng/well of α11-88x8, an antigen described pre-
viously [61, 62]). The coated plates were then washed
three times with PBST (0.01 % Tween 20) and three
times with PBS. The wells were then blocked with 1 %
BSA in PBS for 1 hour at room temperature. Mouse
serum was serially diluted in 1 % BSA in PBS, added to
the wells and incubated at RT for 1 hour. Plates were
washed again as previously described with PBST and
PBS. HRP-conjugated sheep anti-mouse antibody (GE
Healthcare) was added at a dilution of 1:5000 in 1 %
BSA in PBS and incubated at RT for 1 hour. Plates were
washed one final time with PBST and PBS. The plates
were developed for 15 (adenovirus) or 30 (L2) minuteswith the ABTS Peroxidase Substrate System (KPL) and
then optical density was measured at 405 nm using a
microplate reader. Experiments were performed in tripli-
cate and each experiment had duplicates of each sample.
The endpoint ELISA titer was determined as the highest
dilution at which the average optical density of the sam-
ple was greater than twice the average of the negative
control.
Recombinant adenovirus neutralization
1 ml of medium containing 200 pfu of the adenovirus-
HPV recombinant was mixed with an equal volume of
serially diluted mouse sera. The mixture was incubated
at 37 °C for 30 minutes and then 1 mL added to each of
two 6 cm cell culture dishes containing a 293 cell mono-
layer. The virus was adsorbed for 2 hours and the plates
were overlaid with agar medium (MEM without phenol
red containing 0.9 % Bacto-Agar, 2 % FBS, penicillin and
streptomycin). On the third and sixth day later, the cells
were fed with 2.5 mL of agar medium. On day six, the agar
medium contained neutral red and plaques were counted
daily until their numbers became constant [56, 63].
HPV neutralization assays
HPV 16 pseudovirus encapsidating a secreted alkaline
phosphatase (SEAP) reporter plasmid was incubated with
mouse sera for 1 h at RT [64]. The mixture was used to
infect cells in a 96-well plate. 72 h post-infection, the
supernatant was collected and SEAP activity was mea-
sured using a highly sensitive chemiluminescent reporter
system. Serum neutralization titers were defined as the
highest dilution that caused at least a 50 % reduction in
SEAP activity [33].
Statistical analysis
Data were imported into GraphPad Prism 4.03 for prep-
aration of box plots, bar charts or statistical analysis
(mean + SEM). Comparisons of protection between
groups were made by one way ANOVA with Bonferroni
correction. Data are presented as mean + SEM.
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